Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Transcriptome Profile Of Canine HCC

PROVIDER: PRJNA673556 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12961620_1.fastq.gz	Fastqsanger.gz
	SRR12961620_2.fastq.gz	Fastqsanger.gz
	SRR12961621_1.fastq.gz	Fastqsanger.gz
	SRR12961621_2.fastq.gz	Fastqsanger.gz
	SRR12961622_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Project description:Small RNA profile of canine HCC

| PRJNA656856 | ENA

Establishment and characterization of six canine hepatocellular carcinoma cell lines (Transcriptional changes induced by drug treatment with toceranib or sorafenib)

Project description:Hepatocellular carcinoma (HCC) is the most common malignant liver tumor in dogs. Although surgical resection is a major treatment option for canine HCC, there are no distinct strategies for unresectable tumor subtypes or adjuvant chemotherapy for tumors with positive margins. We aimed to establish and characterize novel HCC cell lines from canine patients. The cellular morphology, general growth features and tumorigenicity of the established cell lines were evaluated. We also examined the sensitivity of the cell lines to multi-target tyrosine kinase inhibitors (TKIs). Toceranib, a veterinary TKI that targets vascular endothelial growth factor (VEGFR)/platelet-derived growth factor receptor (PDGFR)/c-kit, effectively inhibited the mitogen-activated protein kinase pathway and induced apoptosis. The established canine HCC cell lines showed greater sensitivity to toceranib than to sorafenib, a first-line treatment for human HCC targeting RAF/VEGFR/PDGFR. Sorafenib showed improved anti-tumor effects when co-treated with SCH772984, an extracellular signal-regulated kinase inhibitor. Our study suggests new therapeutic strategies for canine HCC, and these cell lines are valuable research materials for understanding HCC tumor biology in both humans and dogs.

2024-05-20 | GSE267624 | GEO

Homo sapiens

Project description:HCC Gene Expression Profile

| PRJNA95127 | ENA

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma [ATAC-seq]

Project description:Targeting PRMT5 in canine lymphoma: we characterized expression patterns of PRMT5 in canine lymphomas and correlated these with histological subtypes using tissue microarrays. We characterized expression of PRMT5 in three canine lymphoma-derived cell lines and primary lymph node biopsies. We have demonstrated that inhibition of PRMT5 leads to growth suppression and induction of apoptosis in canine lymphoma cell lines and primary canine lymphoma cells in a time and dose-dependent manner, while selectively decreasing global marks of symmetric dimethylarginine (SDMA) and histone H4 arginine 3 symmetric di-methylation. We performed ATAC-sequencing with pathway enrichment analysis to characterize genome-wide changes in chromatin accessibility after PRMT5 inhibition. We performed gene expression microarrays with pathway analysis to characterize whole transcriptome changes in canine lymphoma cell lines treated with PRMT5 inhibitors. This work validates PRMT5 as a promising therapeutic target for canine lymphoma and supports the continued used of the spontaneously occurring canine lymphoma model for the preclinical development of PRMT5 inhibitors for the treatment of human NHL.

2021-04-20 | GSE156084 | GEO

Comprehensive analysis of Transcriptome Profiles in Hepatocellular Carcinoma patients

Project description:Purpose: The goal of this study is to get a comprehensive evaluation of the transcriptome profile of HCC patients Methods:Transcriptome profiles of paired Tumor and adjacent non-tumour from 25 HCC patients were generated by deep sequencing using the Illumina HiSeq 2000 platform. Paired sample T-test was used to identify differentially expressed genes between Tumours and adjacent non-Tumours. Results: A total of 4462 genes are differentially expressed genes between tumours and adjacent non-tumours Conclusions: Characterization of the transcriptome profiles of HCC patients reveals key genes and pathways that are deregulated in HCC patients.

2020-09-02 | GSE105130 | GEO

Canine Polarized Macrophages Express Distinct Functional and Transcriptomic Profiles

Project description:in the present study we investigate polarized canine macrophages using transcriptome sequencing, a larger panel of flow cytometry markers, and antimicrobial functional assays. Transcriptome analysis of primary canine monocyte-derived macrophages revealed unique, previously unreported signatures for polarized M1 and M2 macrophages.

2022-09-30 | GSE207661 | GEO

Expression data from HIF2A WT vs KD Madin-Darby canine kidney epithelial cells (MDCK strain II cells (ATCC:CCL-34)) under normoxic and hypoxic conditions

Project description:No one pathway was identified in up- and downregulated genes profile in HIF2A KD Madin-Darby canine kidney epithelial cells (MDCKII) in normoxic condition. We used microarray to study the differential expression of genes in HIF2A knockdown versus WT Madin-Darby canine kidney epithelial cells (MDCKII)

2018-10-17 | GSE121325 | GEO

circRNA expression profile in hepatocellular carcinoma (HCC) with metastasis, HCC without metastasis, and non-tumor tissues

Project description:circRNA microArray analysis from Arraystar were used to examine the expression profile in HCC with metastasis, HCC without metastasis, and non-tumor tissues

2022-11-29 | GSE121714 | GEO

Long noncoding RNAs/mRNAs expression profiling for 10 human HCC samples

Project description:To determine the lncRNA expression profile in HCC and matched non-tumor tissues, we used lncRNA microArray analysis form Arraystar to examine the expression of lncRNAs in HCC and matched non-tumor tissues. Goal was to determine the different gene expression between HCC and matched noncancerous tissue.

2018-04-04 | GSE112613 | GEO

Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma [array]

2021-04-20 | GSE155599 | GEO